Everyone in their family may have relatives with cancer. Therefore, the presence of cancer in one family, especially when it has occurred at an early age, is a risk factor for other family members. Hereditary cancers tend to develop earlier in life than sporadic cases.
The Axen™ Hereditary Cancer Panels are designed to detect hereditable and disease-related gene mutations that may help early detection of certain cancers. Early diagnosis can provide physicians with an opportunity from preventive measures to proactive treatments. Eventually, it can become a health guideline for each patient.
- 1) Axen Hereditary Cancer panel 1_16 genes: we check 16 genes related to hereditary cancers. APC, BRCA1, BRCA2, CDH1, EPCAM, MEN1, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, RB1, RET, TP53, VHL
- 2) Axen Hereditary Cancer Panel 2_69 genes: we check 69 genes related to hereditary cancers. TP53, EPCAM, MLH1, MSH2, MSH6, PMS2, PTEN, BRCA2, ATM, BRCA1, APC, CDH1, CHEK2, MUTYH, NBN, PALB2, STK11, VHL, CDK4, CDKN2A, NF1, POLD1, BAP1, BARD1, BMPR1A, BRIP1, HOXB13, MITF, POLE, RAD51C, RAD51D, RB1, SMAD4, TSC1, TSC2, FH, FLCN, MEN1, MET, RET, SDHB, SDHC, SDHD, ALK, DICER1, FANCC, GREM1, MRE11A, NF2, POT1, PTCH1, RAD50, SMARCA4, AIP, AXIN2, BLM, GALNT12, MAX, NTHL1, PHOX2B, PRKAR1A, RECQL, SCG5/GREM1, SDHA, SDHAF2, SMARCB1, SUFU, TMEM127, WT1
- Peripheral blood, DNA
- 2-4 weeks from sample’s arrival at Macrogen’s clinical lab.